Systematic meta-review of depot antipsychotic drugs for people with schizophrenia

C. E. Adams, M. K.P. Fenton, S. Quraishi, A. S. David

Research output: Contribution to journalReview articlepeer-review

283 Scopus citations


Background Long-acting depot antipsychotic medication is a widely used treatment for schizophrenia. Aims To synthesise relevant systematic Cochrane reviews. Method The Cochrane Database was searched and summary data were extracted from randomised controlled clinical trials of depots. Results Standard dose depot v. placebo resulted in significantly less relapse but more movement disorders. Those on depots (v. oral drugs) showed more global change on one outcome measure; relapse and adverse effects showed no difference. Comparisons showed no convincing advantages for one depot over another. Conclusions Depot antipsychotics are safe and effective. They may confer a small benefit over oral drugs on global outcome. Those for whom depots are most indicated may not be represented. Large studies are required to discern differences in relapse rates and long-term adverse effects, and data on satisfaction, quality of life and economics.

Original languageEnglish
Pages (from-to)290-299
Number of pages10
JournalBritish Journal of Psychiatry
Issue numberOCT.
StatePublished - 2001
Externally publishedYes


Dive into the research topics of 'Systematic meta-review of depot antipsychotic drugs for people with schizophrenia'. Together they form a unique fingerprint.

Cite this